-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Morehead City, Winston-Salem
-
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greensboro, Raleigh, Rocky Mount, Statesville
-
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Kinston, Raleigh, Winston-Salem
-
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Cary, Morehead City
-
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Raleigh
-
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham, Fayetteville, Morehead City
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Morehead City, Winston-Salem
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Greensboro, Statesville
-
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Greensboro, Wilmington
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greensboro, Greenville, Morehead City, Statesville
-
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Fayetteville, Morehead City
-
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Raleigh
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greensboro, Morehead City, Wilmington
-
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Monroe
-
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Greensboro, Morehead City, Wilmington
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Morehead City, Shelby
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Greenville, Morehead City
-
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Statesville
-
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Statesville
-
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Greensboro, Morehead City
-
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Morehead City, Raleigh, Statesville
-
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Greensboro, Monroe, Morehead City, New Bern
-
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greensboro, Wilmington
-
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Fayetteville, Greensboro, Morehead City
-
A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)
NCT07355270 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 65 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335 ·
Phase: Phase 3 ·
Ages: 45 Years and older ·
Sex: All (male and female)
· North Carolina: Morehead City, Statesville, Winston-Salem
-
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
NCT05129345 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham
-
CGM for Management of Type 2 Diabetes in Pregnancy
NCT06628453 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 50 Years ·
Sex: Female
· North Carolina: Chapel Hill
-
Continuous Glucose Monitoring, Diabetes Education, and Peer Support for Management of Uncontrolled Type 2 Diabetes
NCT07054125 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Asheville
-
Culturally Tailored Program for Food-Insecure Adults: SPICE-D
NCT07361341 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
NCT06525259 ·
Phase: Not specified ·
Ages: 8 Years to 15 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Winston-Salem
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Cary, Chapel Hill, Greenville, Lenoir
-
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
NCT07521475 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Asheville, Wilmington
-
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· North Carolina: Morehead City
-
Food as Medicine for HIV and Diabetes
NCT05026723 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
NCT07228117 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 7 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Arden
-
Gastroparesis Registry 4
NCT05846802 ·
Phase: Not specified ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Healthy Living Anson Study
NCT07126587 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Human Immunodeficiency Virus (HIV) Food Insecurities
NCT04943861 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
NCT06906640 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
NCT06906627 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Houston
-
Improving Appetite Self-Regulation in African American Adults With Type 2 Diabetes
NCT05741125 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Kannapolis
-
Integrating New Skills Into Diabetes Education With CGM
NCT07463209 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 65 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892 ·
Phase: Phase 4 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham
-
Preventing Type 2 Diabetes in Black Emergent Adult
NCT06848244 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 25 Years ·
Sex: Female
· North Carolina: Chapel Hill
-
Registry for Stage 2 Type 1 Diabetes
NCT06481904 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
NCT06681428 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Raleigh
-
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· North Carolina: Morehead City
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
NCT07271186 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· North Carolina: Greenville, New Bern, Winston-Salem
-
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Morehead City
-
The Treatment of Painful Diabetic Neuropathy With Diet
NCT07509671 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Hendersonville
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Greenville, Morehead City, Wilmington